Patient Information

Pediatric OSA improved with oral montelukast


 

The majority of children with obstructive sleep apnea (OSA) who took oral montelukast showed reductions in their apnea-hypopnea index (AHI) scores, according to the results of a randomized, double-blind placebo-controlled study. Typically, OSA in children is treated with adenotonsillectomy, explained Leila Kheirandish-Gozal, MD, director of clinical sleep research at the University of Chicago, and her colleagues. However, in this study, children were given either montelukast or placebo for 16 weeks and then participated in an overnight polysomnographic study. Seventy-one percent of the patients who took montelukast had fewer AHI events per hour of total sleep time at the end of the study. To learn more, see Family Practice News: http://www.mdedge.com/familypracticenews/article/116479/pulmonology/pediatric-osa-improved-oral-montelukast.

Recommended Reading

CPAP fell short for preventing cardiovascular events
MDedge Family Medicine
Disordered sleep: Ask the right questions to reveal this hidden confounder
MDedge Family Medicine
MRI measurements reveal effects of sleep deprivation
MDedge Family Medicine
Acoustic pharyngometry no additional benefit in OSA diagnosis
MDedge Family Medicine
MRI measurements reveal effects of sleep deprivation
MDedge Family Medicine
Pediatric OSA improved with oral montelukast
MDedge Family Medicine
Treatment plan addresses circadian rhythm disorders from nighttime screen use
MDedge Family Medicine
Adaptive servo ventilation cuts atrial fib burden
MDedge Family Medicine
Tips for sleep hygiene: A handout for patients
MDedge Family Medicine
Roommates
MDedge Family Medicine